Related Experiment Video
Updated: Jun 3, 2025
Author Spotlight: Enhancing Bone Regeneration with Vascularized Artificial Cartilage Integration
Published on: July 14, 2023
Latest Developments in Targeted Biological Therapies in the Management of Chordoma and Chondrosarcoma
Adam Biczo1, Arjun Sahgal2, Jorrit-Jan Verlaan3
1National Center for Spinal Disorders and Buda Health Center, Budapest, Hungary.
Study Design:
Systematic review.
Objectives:
The objective of this review paper was to summarize targeted molecular therapy options for spinal chordoma and chondrosarcoma, and to provide an update on the relevant clinical trials open for recruitment.
Methods:
A systematic review of the current literature was performed, according to PRISMA guidelines, to summarize the latest developments in non-surgical molecular treatment options for low grade malignant primary spinal tumours. We also summarize those actively recruiting clinical trials based on clinicaltrials.gov.
Results:
A total of 73 studies and completed clinical trials were reviewed. Twenty actively recruiting clinical trials (eight for chordoma and twelve for chondrosarcoma) were identified.
Conclusions:
There is a strong need to find new therapeutic options to complement surgical resection and radiation therapy, which remain the cornerstone of management. Targeted therapies against molecular pathways show promise as compared to conventional chemotherapy.
Insights
Targeted molecular therapies show promise for spinal chordoma and chondrosarcoma, offering new options beyond surgery and radiation. This review identifies 20 actively recruiting clinical trials for these rare tumors.
Area of Science:
- Oncology
- Orthopedic Surgery
- Molecular Biology
Background:
- Spinal chordoma and chondrosarcoma are rare primary bone tumors.
- Current management relies on surgery and radiation, with limited non-surgical options.
- There is a need for novel therapeutic strategies to improve outcomes.
Purpose of the Study:
- To review targeted molecular therapy options for spinal chordoma and chondrosarcoma.
- To update on actively recruiting clinical trials for these conditions.
- To explore non-surgical treatment advancements.
Main Methods:
- Systematic literature review following PRISMA guidelines.
- Searched for studies on molecular treatments for spinal tumors.
- Identified clinical trials from clinicaltrials.gov.
Main Results:
- Reviewed 73 studies and completed clinical trials.
- Identified 20 actively recruiting clinical trials.
- Eight trials for chordoma and twelve for chondrosarcoma were found.
Conclusions:
- Targeted therapies targeting molecular pathways show promise.
- These therapies could complement existing treatments like surgery and radiation.
- Further research and clinical trials are crucial for these rare tumors.
